Chikungunya virus inhibition by synthetic coumarin–guanosine conjugates

Article abstract of DOI:10.1016/j.ejmech.2019.01.037

Since its discovery in Tanganyika, Africa in 1952, chikungunya virus (CHIKV) outbreaks have occurred in Africa, Asia, Europe, and America. Till now chikungunya fever has spread in nearly 40 countries. Because of lack of effective vaccines and antiviral dr

Full text of DOI:10.1016/j.ejmech.2019.01.037

Accepted Manuscript
Chikungunya virus inhibition by synthetic Coumarin−Guanosine conjugates
Jih Ru Hwu, Wen-Chieh Huang, Shu-Yu Lin, Kui-Thong Tan, Yu-Chen Hu, Fa-Kuen
Shieh, Sergey O. Bachurin, Aleksey Ustyugov, Shwu-Chen Tsay
PII:
S0223-5234(19)30047-9
DOI:
https://doi.org/10.1016/j.ejmech.2019.01.037
EJMECH 11044
Reference:
To appear in: European Journal of Medicinal Chemistry
Received Date: 16 June 2018
Revised Date: 18 October 2018
Accepted Date: 15 January 2019
Please cite this article as: J.R. Hwu, W.-C. Huang, S.-Y. Lin, K.-T. Tan, Y.-C. Hu, F.-K. Shieh,
S.O. Bachurin, A. Ustyugov, S.-C. Tsay, Chikungunya virus inhibition by synthetic Coumarin
−Guanosine conjugates, European Journal of Medicinal Chemistry (2019), doi: https://doi.org/10.1016/
j.ejmech.2019.01.037.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT
Graphical abstract
R1
R2
three new conjugates
against CHIKV
activity
O
O
R1 or R2 :
EC50 = 9.9–13.9 µM
CC50 = 96.5–212 µM
SI = 9.37–21.7
CH2
–OMe >> H, F, Cl, Br, Me
R1
S
N
N
S
R3
N
N
H2N
= essential
or
O
R3 =
R2
O
HO
enhancing
water solubility
O
OH
HO
1

ACCEPTED MANUSCRIPT
Chikungunya Virus Inhibition by Synthetic Coumarin−Guanosine Conjugates
Jih Ru Hwu, a,b,c,* Wen-Chieh Huang,a,b Shu-Yu Lin,a,b Kui-Thong Tan,a,b Yu-Chen Hu,b,d
Fa-Kuen Shieh,c Sergey O. Bachurin,e Aleksey Ustyugov,e and Shwu-Chen Tsay a,b,c,
*
aDepartment of Chemistry, National Tsing Hua University, Hsinchu 300, Taiwan
bFrontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing
Hua University, Hsinchu 300, Taiwan
cDepartment of Chemistry, National Central University, Jhongli City, Taoyuan 320, Taiwan
dDepartment of Chemical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan
eThe Institute of Physiologically Active Compounds, Russian Academy of Sciences,
Chernogolovka 142432, Russia
* Corresponding Author
E-mail addresses: jrhwu@mx.nthu.edu.tw (J.R. Hwu),
tsay.susan@gmail.com (S.-C. Tsay).
Keywords: Chikungunya virus, Coumarin, Guanosine, Conjugate, Thiomethylene
ABSTRACT
Since its discovery in Tanganyika, Africa in 1952, chikungunya virus (CHIKV) outbreaks
have occurred in Africa, Asia, Europe, and America. Till now chikungunya fever has
spread in nearly 40 countries. Because of lack of effective vaccines and antiviral drugs to
intervene this disease, 21 new conjugated compounds were designed and synthesized by
coupling of 6,8-dithioguanosine at its C-6 position with 3-(chloromethyl)coumarins bearing
an F, Cl, Br, Me, or –OMe substituent through the –SCH2– joint. Meanwhile, an organic
“dummy” ligand (e.g., methyl, benzyl, and naphthylmethyl) or a coumarinyl moiety was
attached at the C-8 position. By high through-put screening, three of these new conjugates
were found to inhibit CHIKV in Vero cells with significant potency (EC50 = 9.9–13.9 µM)
and showed low toxicity (CC50 = 96.5–212 µM). The selectivity index values were 9.37–
21.7. Their structure–activity relationship was deduced, which indicates that the coumarin
moiety is essential and the presence of a –OMe group enhances the antiviral activity.
1

ACCEPTED MANUSCRIPT
1. Introduction
As an emerging disease, chikungunya (CHIK) fever causes a major medical problem at
the present time. In 1952, this arboviral disease was first recognized in East Africa [1].
There were >146,900 confirmed cases in 2016, including those from Africa, Argentina,
Brazil, Bolivia, and Colombia. The CHIK illness is characterized by abrupt onset of fever,
headache, fatigue, nausea, vomiting, rash, myalgia, and severe arthralgia. This disease often
incurs serious economic and social impact on the individual and even the communities [2].
Unfortunately, current treatments of CHIK fever are merely for symptoms with no effective
licensed vaccine [3]. Even worse is that the current world still has no specific antiviral drug
for the treatment of the CHIK fever.
In addition to the antiviral agents described in a recent review article [4], the drug
chloroquine [5] exhibits cellular anti-viral effect on chikungunya virus (CHIKV) infection.
Nevertheless, its utilization has been proved to be poorly active in vivo. Scientists also
devoted numerous efforts to develop β-amyrone, apigenin, chrysin, 5,7-dihydroxy flavones,
lupenone, mycophenolic acid, prothipendyl, silibin, et al. as anti-CHIKV agents.
Nevertheless, these compounds only show weak efficacy [6]. Moreover, trigocherrierin A
was found with an EC50 value of 0.6 ± 0.1 µM and an SI value of 71.7 [6e].
Recently, a thorough review article on >20 classes of antiviral agents has been reported
by da Silva-Júnior and co-workers [7]. Pérez–Pérez et al. disclosed their synthetic
triazolopyrimidinones and Chai et al. disclosed new thienopyrroles with significant
anti-CHIKV activity [8a,b].
van Hermert et al. also found that bis(benzofuran–
thiazolidinone)s and bis(benzofuran–thiazinanone)s inhibit CHIKV replication in Vero E6
cells with an EC50 value as low as 1.9 µM and SI value as high as 75 [8c]. At present,
scientific community is eager to obtain new compounds with favorable potency and SI values
so that an effective anti-CHIKV drug may emerge. It is our plan to develop new leads to
inhibit CHIKV by synthesizing a series of nucleoside derivatives with the general structures
1. The conjugative frameworks were designed to contain three essential parts: a coumarin
nucleus, a guanosine moiety, and a thiomethylene (–SCH2–) joint.
Coumarins exist in a diverse range of plant sources as well as certain microorganisms
and animals [9]. These natural products display an extraordinarily wide range of biological
activities with therapeutic values. An example is 7-hydroxy-4-methylcoumarin, which was
investigated as a lead in cancer-drug development [10]. Synthetic coumarins are found to
possess different pharmacological or biological activities or both, such as antiviral [11–14],
anticoagulant [15], anti-inflammatory [16], antimutagenic [17], antitumor [18], antitubercular
[19], CNS stimulant [20], fungicidal [21], scavenger of oxygen species [22], and vasodilator
2

ACCEPTED MANUSCRIPT
activities [23]. Some planar coumarin derivatives function as DNA intercalators and have
been used in cancer treatment [24]. Recently, coumarins conjugated with various organic
moieties have been synthesized [12,13].
These moieties include benzimidazoles,
benzothiazoles, benzoxazoles, benzouracils, heterobicycles, imidazoles, imidazopyridines,
and purine ribofuranosides. The resultant conjugates exhibit appealing anti-HCV activity
and become promising leads for their further development as drugs [13].
The frameworks of 1 as shown below contain a 6-thioguanine moiety in common.
6-Thioguanine is a medication for the treatment of several types of leukemia [25a], ulcerative
colitis, autoimmune diseases [25b], and HIV [25c]. Herdewijn et al. [26] synthesized
8-thiol-6-thioguanine derivatives, which act as potent inhibitors of human nucleotide
pyrophosphatase/phosphodiesterase 1. These enzymes can hydrolyze phosphodiester bonds
in a wide variety of substrates. Accordingly, inhibitors of these enzymes hold promise for
the treatment of diabetes and tumors.
X
8'
6'
= nucleophilic center
= electrophilic site
coumarin
O
O
thiomethylene
S
6
7
N
1
N
8
R = lipophilic moiety
SR
2
N
H2N
HO
N
3
5''
guanosine
O
hydrophilic hydroxyl groups
3''
2''
OH OH
1
X
X = H, F, Cl, Br, Me, OMe
R = Me,
O
,
,
O
Guanosine provides multiple functional groups for medicinal chemists to manipulate
during the development of their derivatives as drug leads. The C-6 and C-8 positions can be
used for its attachment to a conjugated component as shown in the structures 1. The three
hydroxyl groups at the C-2′′, C-3′′, and C-5′′ positions of a ribose would improve the
solubility of the conjugates in the aqueous medium. Furthermore, the free amino group at
the C-2 position of guanine may form hydrogen bonds with substrates. The thiomethylene
(–SCH2–) unit therein serves the purpose of a joint, which performs better efficacy than
others [4], such as methylene (–CH2–), aminoethylene (–NHCH2–), amido (–CONH–), urea
(–NHCONH–), ureide (–CONHCONH–), and directly hinged (–) units. This is based on
3

ACCEPTED MANUSCRIPT
our results during the development of new conjugated compounds with antiviral activities
[13d].
Herein the synthesis of 21 new conjugated compounds with the frameworks of 1 is
reported. Their anti-CHIKV activity was evaluated and a structure–activity relationship was
elucidated. The results indicate that the lowest EC50 value of coumarin−guanosine
conjugates was 9.9 µM and the highest SI value reached 21.7.
2. Results
During the synthesis of target molecules with the chemical scaffolds 1, three challenges
were encountered when performed a coupling reaction in the key step. These challenges
were related to the active sites of the starting materials thioguanosine substrates and coumarin
reagents, as well as those in the desired conjugated products. The thioguanosine nucleus
has nine nucleophilic centers, including one NH2 group attached to the C-2 position, three
nitrogen atoms at the C-1, C-3, and C-7 positions, two sulfur atoms attached to the C-6 and
C-8 positions, and three OH groups attached to the C-2′′, C-3′′, and C-5′′ positions.
Meanwhile, coumarin reagents have three electrophilic sites, including an allyl halide, a
lactone, and an α,β-unsaturated ester. Finally, when the desired conjugated products 7 and
14 are formed, they may not be stable under the conditions for their generation. Thus a
coumarin moiety needs to be incorporated to the thioguanosine nucleus in an appropriate step
during their synthesis. The reaction conditions have also to be mild enough so that a
competitive Michael addition would not take place at the α,β-unsaturated ester group.
Moreover, a 1,2-addition would not occur either to induce a ring-opening of the δ-lactone
moiety. Given all these concerns, two different sequential synthetic routes as shown in
Schemes 1 and 2 were developed for the production of the conjugated targets 7 and 14.
2.1. Synthesis of new biscoumarin–dithioguanosine conjugates 7 (Scheme 1)
For the incorporation of sulfur atoms at the C-6 and C-8 positions of 8-bromoguanosine
2 [27], it was first activated by use of phosphorus oxychloride in the presence of
(N,N-dimethyl)isopropylamine in acetonitrile. The resultant chloride 3 was then treated
with an excess of thiourea in ethanol to give dithio intermediate 4. The three acetyl
protecting groups of 4 were then removed by potassium carbonate in methanol to give triol 5.
The last step was the coupling of triol 5 (1.0 equiv) with 3-(chloromethyl)coumarins 6a–
g (2.0 equiv); the latter compounds were prepared in three steps by use of the established
procedures [14a]. Various substituents, including F, Cl, Br, Me, and –OMe, were attached
at the C-6′ or C-8′ position of the coumarins 6. Among numerous trials of the conditions for
4

ACCEPTED MANUSCRIPT
the coupling reaction, the desired biscoumarin–dithioguanosine conjugates 7a–g were
obtained as yellow solids. These reaction conditions were optimized to give the best yields
(70–85%) by use of 35% ammonium hydroxide in aqueous acetonitrile at room temperature
for 40 min to 3.0 h. This synthetic route led to the target conjugates with two identical
coumarin moieties attached to the central guanosine nucleus through a thiomethylene joint.
Cl
6
O
6
S
6
S
N
N
N
N
N
N
N
HN
H2N
8
8
HN
8
POCl3
N(i-Pr)Me2
Br
Br
SH
K2CO3
H2N
NH2
H2N
AcO
N
N
H2N
AcO
N
MeOH, r.t.
(82%)
EtOH
reflux
(78%)
CH3CN
reflux
(72%)
AcO
O
O
O
OAc OAc
OAc OAc
OAc OAc
3
4
2
R1 6'
8' R2
O
1. NH4OH (aq)
yield (%)
6' R1
6
&
a
b
c
d
e
f
7
R1:
H
R2:
of
7
S
6
Cl
2.
O
8
H
70
N
HN
8
O
O
8'
SH
F
H
78
72
80
80
85
77
S
6
R1
R2
6
N
6'
H2N
HO
N
Cl
H
N
N
N
CH3CN, H2O
S
O
Br
H
r.t.
(70–85%)
8'
R2
H2N
HO
N
Me
OMe
H
H
O
OH OH
O
O
H
5
g
OMe
7
OH OH
Scheme 1. Synthetic procedure for the generation of conjugated compounds 7 containing
two coumarin moieties with different substituents
2.2. Synthesis of new monocoumarin–dithioguanosine conjugates 14 (Scheme 2)
Alternative synthetic routes were developed to produce monocoumarin–dithioguanosine
conjugates 14. In all of these 11 target conjugates, a coumarin moiety was attached at the
C-6 position through a thiomethylene joint. The S atom at the C-8 position was attached
with a “dummy” ligand, including alkyl and aryl groups.
Selective mono-alkylation of thioguanosine 8 [28] was performed at its C-8 thiol group
before the coumarin moiety was incorporated at the C-6 position in the final conjugated
targets (Scheme 2). The methylation with MeI took place preferentially at the C-8 thiol
group by use of 35% aqueous ammonia in acetonitrile for 6.0 h. Under these conditions, the
desired 8-(methylthio)guanosine (9a) was generated with a yield better than the reported one
(82% versus 70%) [29]. Its IR spectrum showed a strong absorption band at 1697 cm–1 very
close to the reported 1696 cm–1, which was associated with the C-6 carbonyl stretching
vibration of the thioguanosine moiety in 8. The spectroscopic data clearly indicate that the
5

ACCEPTED MANUSCRIPT
C-6 carbonyl group of thioguanosine 8 remained intact and its alkylation took place at the
C-8 thiol group to produce the methylthioether 9a.
O
O
O
6
N
N
N
N
N
N
HN
HN
HN
8
SH
S
S
Ac2O, NEt3
DMAP
1. NH4OH (aq)
R3
R3
2. R3CH2X (X = Br, I)
H2N
HO
N
H2N
HO
N
H2N
AcO
N
CH3CN, H2O, r.t.
(71–82%)
CH3CN, r.t.
(70–75%)
O
O
O
OH OH
OH OH
OAc OAc
8
9
10
Cl
S
N
N
S
N
HN
POCl3
N(i-Pr)Me2
S
S
9
–13
R3:
H
R3
R3
H2N
NH2
N
N
N
H2N
AcO
N
H2N
AcO
a
CH3CN
reflux
(50–60%)
EtOH
reflux
b
c
Ph
O
O
C10H7
(62–76%)
OAc OAc
OAc OAc
11
12
1. NH4OH (aq)
6
a
c
d
e
f
R1:
H
R2:
H
R1
S
Cl
2.
6
N
HN
S
O
O
Cl
H
K2CO3
MeOH
R3
N
N
R2
H2N
HO
6
Br
H
Me
H
O
r.t.
CH3CN, H2O
(75–84%)
OMe
H
H
r.t.
(70–86%)
OH OH
g
OMe
13
14
a
b
c
d
e
f
R1:
R2:
R3:
yield (%)
1 6'
R
R2
8'
H
H
H
H
70
76
80
79
82
74
81
83
86
75
85
Cl
Br
H
O
H
H
O
8
Me
H
H
H
S
–OMe
H
H
6
N
N
H
Ph
Ph
Ph
Ph
C10H7
C10H7
N
S
R3
g
h
i
Cl
H
H2N
HO
N
B
r
H
O
–OMe
H
H
j
H
OH OH
k
–OMe
H
14
Scheme 2. Synthetic procedure for the generation of conjugated compounds 14 containing
one coumarin moiety and a “dummy” ligand
For activation of the C-6 position and subsequent incorporation of a sulfur atom,
phosphorus oxychloride was used. Thus the three free hydroxyl groups of triol 9a were
protected by use of acetic anhydride to give the corresponding triacetate 10a, which was then
6

ACCEPTED MANUSCRIPT
chlorinated with phosphorus oxychloride to produce the intermediate 11a. Reaction of the
chloride 11a with thiourea yielded the thione 12a, in which the three acetyl protecting groups
were then removed under the same conditions (i.e., K2CO3 in methanol) applied previously
for the conversion of 4 to 5. In the final step, S-alkylation was carried out at the C-6
position of thione 13a (1.0 equiv) with various coumarins 6 (1.5 equiv) to give the desired
monocoumarin–guanosine conjugates 14a–e in 70–82% yields.
Applied the same synthetic strategy and reaction conditions shown in Scheme 2, a
benzyl (from benzyl bromide) and a naphthylmethyl (from 1-naphthylmethyl bromide)
groups were also incorporated into thioguanosine 8 to produce the corresponding aralkylated
thioguanosines 9b and 9c [30]. These intermediates were then converted to the desired
coumarin-conjugated compounds 14f–k, which were subjected to biological assays.
The total syntheses of coumarin–thioguanosine conjugates shown in Schemes 1 and 2
shared a common strategy:
the coupling reactions between coumarins 6 and
thionguanosines (5 and 13a–c) were performed in the final step. It was due to the instability
of the conjugated targets 7a–g and 14a–k. The purity of all new compounds was ≥98.1%,
which was obtained by gravity chromatography and then determined by HPLC.
2.3. Structural identification of new conjugated compounds
The structures of all new compounds were determined on the basis of their spectroscopic
characteristics. For example, the mass spectrum of biscoumarin–guanosine 7f obtained by
fast atom bombardment mass spectrometry had a molecular mass of 707.1363 for the species
M+ with the molecular formula C32H29N5O10S2, which is close to the theoretical value of
707.1356. Its 13C NMR spectrum contained 32 peaks and had resonance at δ 31.71 and
27.23 ppm for the two SCH2 carbons. The two peaks at 160.43 and 160.21 ppm were
associated with the carbons of the two –O–C=O functionalities in the coumarin moieties.
The resonance at 88.08 ppm belonged the glycosidic C-1′′ carbon. In its 1H NMR spectrum,
the characteristic doublet with J = 6.4 Hz at 5.63 ppm was attributed to the glycosidic proton
[31]. Its IR spectrum showed a strong absorption band at 1708 cm–1, which was associated
with the carbonyl stretching vibration of the coumarin moiety [32].
The target 14k represents an example for the structural identification of monocoumarin–
guanosine conjugates. Its 13C NMR spectrum had one peak at around 36.66 ppm, which
was correlated to the carbon of the C-8 SCH2 unit; it is comparable with the peak at δ 36.88
ppm for compound 13c. The peak at δ 28.20 ppm was assigned to the carbon of the C-6
SCH2–coumarin moiety; it is comparable with the peak at δ 27.23 ppm for the compound 7f.
7

ACCEPTED MANUSCRIPT
Moreover, the spectrum of conjugated compound 14k had only one peak around 160.36 ppm,
which was attributed to the –O–C=O carbon of the exclusive coumarin moiety.
2.4. Biological activity against CHIKV
The biological activity of the conjugated coumarin–guanosine against the CHIKV (899
strain) was primarily evaluated in Vero cells subtype A by the Bassetto procedures [33].
The concentrations of conjugates that inhibited virus replication by 50% (i.e., EC50) were
calculated on the basis of the obtained dose-response curves and listed in Table 1. The
concentrations to reduce host cell metabolism by 50% (i.e., CC50) were obtained only for
promising compounds that exhibited significantly low EC50 values. The selectivity index
(SI = CC50/EC50) was then calculated. It is a measure for the therapeutic window of the
compound in the assay system. The antiviral effect of conjugated compounds that adversely
affected the host cell metabolism was likely as a result of a pleiotropic or non-specific effect
on the host cell.
Among these 21 new compounds tested through high through-put screening, we found
that 7f, 7g, and 14k exhibited compelling potency in CHIKV Vero cells with EC50 values
ranging from 9.9 to 13.9 µM (Table 1). They displayed a significant window of selectivity
with SI values between 9.37 and 21.7.
2.5. Measurement of Lipophilicity
Molecular lipophilicity, often quantified as log P [34], is a major factor to be considered
during the development of chemical entities as drug leads. A good range for the log P
values is between –0.4 and 5.6 for drug-like molecules [35]. When the calculated log P is
greater than 5, poor absorption or permeation is likely to occur [36]. An example is
chloroquine with a log P value of 5.3; it is a medication used to prevent and to treat malaria.
Hence the ‘‘shake–flask method’’ [37] was applied to obtain the log P values of the newly
synthesized conjugated compounds 7e, 7f, 7g, 14i, and 14k as well as dithioguanosine 5 for
comparison (Table 1). Our data show that the molecular lipophilicity values of the five
coumarin–guanosine conjugates were between 2.78 and 3.77, which are considered in the
good range for drug-like molecules.
3. Discussion
Coumarinyl, methyl, benzyl, and naphthylmethyl groups were introduced onto the
dithioguanosine nucleus to form the conjugated compounds shown in Schemes 1 and 2 for
the study of their structure–activity relationship toward CHIKV. Different substituents,
8

ACCEPTED MANUSCRIPT
Table 1
Inhibitory effects of conjugated compounds on CHIKV (899 strain) in Vero cells subtype A
and their lipophilicity.
compound
CC50a (µM)
EC50b (µM)
SIc
log P
ND
ND
ND
ND
ND
81.3
>212
96.5
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
>227
>302
>154
>146
>140
>124
40.9
NA
NA
NA
NA
NA
–0.13
5
–
–
7a
7b
–
7c
–
7d
1.98
3.22
3.01
2.97
–
7e
9.9
>21.7
9.37
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
>16.3
7f
10.3
7g
>237
>212
>198
>186
>172
>194
>188
>173
>163
>152
>164
>159
13.9
13b
13c
14a
14b
14c
14d
14e
14f
14g
14h
14i
14j
14k
–
–
–
–
–
–
–
–
–
2.78
–
3.77
3-[(methylthio)-
methyl]coumarin
NA
>485
NA
–
ND = not detected; NA = not available
9

ACCEPTED MANUSCRIPT
a
The concentration of a compound with an adverse effect of 50% was observed on the host
b
cell metabolism, as determined by the MTS method; The concentration of a compound at
which virus replication was inhibited by 50% was observed, as determined by real-time
quantitative RT–PCR; c Selectivity index.
including F, Cl, Br, Me, and –OMe, were attached to the coumarin moiety to investigate their
influence on the antiviral activity. According to the EC50, CC50, SI, and log P values of all
new compounds listed in Table 1, the following SAR guidelines are deduced for their activity
against CHIKV.
(1) The parent dithioguanosine 5 (EC50 >302 µM) did not show antiviral activity toward
CHIKV. After its C-8 thione functionality was alkylated with a benzyl or naphthylmethyl
group, the resultant compounds 13b and 13c still did not show anti-CHIKV activity. After a
coumarin moiety was attached to these dithioguanosines 5 and 13 through a –SCH2– joint,
the conjugated compounds 7f, 7g, and 14k exhibited potency with EC50 values <13.9 µM.
Thus the coumarin is an essential moiety for these new conjugated compounds to have
antiviral activity toward CHIKV.
(2) When the C-8 coumarinyl moiety in biscoumarin–guanosine conjugate 7f was replaced
by a biologically “dummy” naphthyl moiety (i.e., 14k), its anti-CHIKV activity retained.
The size and the planarity of a naphthyl moiety are similar to those of the coumarinyl moiety.
Nevertheless, the biological activity diminished in a great extent when the coumarinyl moiety
in conjugate 7f was replaced by a smaller benzyl group (i.e., 14i).
(3) Among various electron-withdrawing and -donating groups, including F, Cl, Br, Me,
and –OMe, the coumarin–guanosine conjugates containing the –OMe group in the coumarin
moiety (i.e., 7f, 7g, and 14k) exhibited much greater anti-CHIKV activity than conjugates
bearing other substituents.
(4) Lipinski [38] reported the requirement of a minimum aqueous solubility of 5.2 mg/100
mL for a compound with medium intestinal permeability to achieve oral absorption.
6-Methoxycoumarin derivative 6f coupled with guanosine derivative 5 gave the conjugated
compound 7f, which had three free hydroxyl groups. Its solubility was measured as 7.2
mg/100 mL, which fits into the Lipinski’s requirement for oral absorption.
4. Conclusions
Twenty one new compounds, including 19 coumarin–thioguanosine conjugates, were
synthesized and their antiviral activity toward CHIKV was investigated. Conjugates 7f, 7g,
10

ACCEPTED MANUSCRIPT
and 14k were found to impede CHIKV replication at EC50 values of 9.9, 10.3, and 13.9 µM,
respectively. Their SI values ranged from 9.37 to 21.7. The coumarin moiety in these
conjugated compounds was proven to be essential. By possessing three free hydroxyl
groups, the three conjugate drug leads showed lipophilicity and water solubility that are fitted
into the suggested physical properties of pharmaceuticals. Moreover, our guidelines of SAR
provide valuable information for design and synthesis of new antivirals. Development of
new coumarin-containing conjugates with antiviral activities on a broad spectrum against
other essential, emerging, and neglected RNA viruses is in progress. The results will be
reported in due course.
5. Experimental Section
5.1. Standard Procedure for the Synthesis of Guanosine–Coumarin Conjugates 7f, 7g, and
14k
To a solution containing a thione (5 or 13c, 1.0 equiv) in water (2.5 mL) and acetonitrile
(1.5 mL) was added saturated aqueous ammonium hydroxide (0.10–0.15 mL). To the
solution stirred at room temperature for 30 min was added a coumarin 6f or 6g (2.0 equiv for
5; 1.5 equiv for 13c). The reaction mixture was stirred at room temperature for 1.0 h.
After acetonitrile was removed under reduced pressure, the residue was treated with 20%
aqueous NaHCO3 solution (30 mL). The aqueous phase was extracted with CH2Cl2 (3 × 25
mL), and the combined organic layers were then washed with brine (30 mL), dried over
MgSO4 (s), filtered, and concentrated under reduced pressure to afford a residue. The
residue was purified by use of column chromatography packed with silica gel to give the
desired product 7f, 7g, or 14k.
5.1.1.2-Amino-6,8-bis[(6′-methoxycoumarin-3′-yl)methylthio]-9-(β-D-ribofuranos-1′′-
yl)purine (7f)
The standard procedure was followed by use of guanosine-6,8-dithione (5, 35.3 mg,
0.107 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.15 mL), and coumarin 6f (46.7 mg,
0.208 mmol, 2.0 equiv). After the solution was stirred at room temperature for 1.0 h and
then worked up, the residue was purified by use of column chromatography (5.0% MeOH in
EtOAc as the eluent) to give biscoumarin 7f (64.2 mg, 45.5 µmol) in 85% yield as yellow
1
solids: mp (recrystallized from CH2Cl2/MeOH) 270.2–272.0 °C; H NMR (DMSO-d6, 400
MHz) δ 8.30 (s, 1 H, H-4′), 8.07 (s, 1 H, H-4′), 7.34–7.31 (m, 2 H, 2 × ArH), 7.23 (s, 1 H,
ArH), 7.16–7.12 (m, 2 H, ArH), 711–7.09 (m, 1 H, ArH), 6.65 (s, 2 H, NH2), 5.63 (d, J = 6.4
Hz, 1 H, H-1′′), 5.38–5.36 (m, 1 H, OH), 5.12–5.09 (m, 1 H, OH), 4.98–4.93 (m, 2 H, OH +
H-2′′), 4.34–4.31 (m, 4 H, 2 × SCH2), 4.11–4.07 (m, 1 H, H-3′′), 4.01–3.98 (m, 1 H, H-4′′),
3.74 (s, 3 H CH3), 3.66 (s, 3 H, CH3), 3.66–3.59 (m, 1 H, H-5′′), 3.51–3.49 (m, 1 H, H-5′′);
11

ACCEPTED MANUSCRIPT
13C NMR (DMSO-d6, 100 MHz) δ160.43 (C=O), 160.21 (C=O), 158.53, 156.35, 155.68,
155.48, 152.46, 147.50, 147.29, 147.15, 141.73, 141.28, 124.99, 124.34, 123.84, 119.47,
119.40, 119.13, 118.94, 117.21, 117.12, 110.45, 110.23, 88.08, 85.93, 70.55, 70.36, 61.95,
55.66 (OCH3), 55.63 (OCH3) 31.71 (SCH2), 27.23 (SCH2); IR (neat) 3349 (br, NH + OH),
2924 (w), 1708 (s, C=O), 1609 (m), 1478 (m), 1273 (m), 1190 (m) cm−1; HRMS (FAB+)
calcd m/z [M]+ for C32H29N5O10S2 707.1356, found 707.1363.
5.1.2.2-Amino-6,8-bis[(8′-methoxycoumarin-3′-yl)methylthio]-9-(β-D-ribofuranos-1′′-
yl)purine (7g)
The standard procedure was followed by use of guanosine-6,8-dithione (5, 32.0 mg,
96.6 µmol, 1.0 equiv), aqueous ammonium hydroxide (0.15 mL), and coumarin 6g (43.4 mg,
193 µmol, 2.0 equiv). After the solution was stirred at room temperature for 1.0 h and then
worked up, the residue was purified by use of column chromatography (5.0% MeOH in
EtOAc as the eluent) to give biscoumarin 7g (52.5 mg, 74.3 µmol) in 77% yield as yellow
1
solids: mp (recrystallized from CH2Cl2/MeOH) 270.8–272.2 °C; H NMR (DMSO-d6, 400
MHz) δ 8.31 (s, 1 H, H-4′), 8.06 (s, 1 H, H-4′), 7.24–7.21 (m, 3 H, 3 × ArH), 7.20–7.17 (m, 3
H, 3 × ArH), 6.65 (s, 2 H, NH2), 5.59–5.58 (m,1 H, H-1′′), 5.34–5.33 (m, 1 H, OH), 5.09–
5.08 (m, 1 H, OH), 4.96–4.93 (m, 2 H, OH + H-2′′), 4.33–4.31 (m, 4 H, 2 × SCH2), 4.08–4.04
(m, 1 H, H-3′′), 4.00–3.98 (m, 1 H, H-4′′), 3.88 (s, 3 H CH3), 3.84 (s, 3 H, CH3), 3.60–3.54
(m, 1 H, H-5′′), 3.46–3.42 (m, 1 H, H-5′′); 13C NMR (DMSO-d6, 100 MHz) δ 160.26 (C=O),
160.04 (C=O), 158.36, 156.18, 155.51, 155.29, 152.29, 147.33, 141.56, 141.11, 124.89,
124.17, 123.67, 119.30, 119.23, 118.96, 118.77, 117.04, 116.94, 110.27, 110.06, 87.91, 85.76,
70.53, 70.09, 61.78, 55.64 (OCH3), 55.36 (OCH3), 31.54 (SCH2), 27.06 (SCH2); IR (neat)
3349 (br, NH + OH), 2924 (w), 1708 (s, C=O), 1609 (m), 1478 (m), 1273 (m), 1190 (m) cm−1;
HRMS (FAB+) m/z [M]+ calcd for C32H29N5O10S2 707.1356, found 707.1371.
5.1.3.2-Amino-6-(6′-methoxycoumarin-3′-yl)methylthio-8-(1′′-naphthylmethylthio)-
9-(β-D-ribofuranos-1′′′-yl)purine (14k)
The standard procedure was followed by use of thione 13c (20.2 mg, 42.8 µmol, 1.0
equiv), aqueous ammonium hydroxide (0.10 mL), and coumarin 6f (14.41 mg, 643 µmol, 1.5
equiv). After the solution was stirred at room temperature for 1.0 h and then worked up, the
residue was purified by use of column chromatography (5.0% MeOH in EtOAc as the eluent)
to give conjugate 14k (23.9 mg, 36.3 µmol) in 85% yield as yellow solids: mp
(recrystallized from CH2Cl2/MeOH) 178.2–179.5 °C; 1H NMR (DMSO-d6, 400 MHz) δ 8.36
(s, 1 H, H-4′), 7.84–7.83 (m, 1 H, ArH), 7.82–7.81 (m, 1 H, ArH), 7.61–7.56 (m, 2 H, 2 ×
ArH), 7.43–7.41 (m, 3 H, 3 × ArH), 7.29–7.26 (m, 3 H, 3 × ArH), 6.65 (br, 2 H, NH2), 5.63–
5.60 (m, 1 H, H-1′′′), 5.37–5.36 (m, 1 H, OH), 5.13–5.12 (m, 1 H, OH), 5.09–4.98 (m, 1 H,
OH), 4.93–4.91 (m, 1 H, H-2′′′), 4.51 (m, 2 H, ArCH2S), 4.33–4.31 (br s, 2 H, SCH2CCO),
4.32–4.28 (m, 2 H, H-3′′′ + H-4′′′), 3.89 (s, 3 H, OCH3), 3.59–3.56 (m, 1 H, H-5′′′), 3.48–3.46
12

ACCEPTED MANUSCRIPT
(m, 1 H, H-5′′′); 13C NMR (CDCl3, 100 MHz) δ 160.36 (C=O), 159.25, 157.09, 153.12,
152.23, 152.15, 147.97, 145.27, 142.33, 138.56, 138.22, 135.62, 134.17, 131.73, 131.23,
131.20, 129.38, 129.18, 128.74, 126.90, 126.33, 126.04, 125.72, 123.91, 86.90, 79.75, 72.11,
70.47, 62.93, 55.62 (OCH3), 36.66 (ArCH2S), 28.20 (SCH2CCO); IR (neat) 3335 (br, NH +
OH), 2922 (w), 1720 (s, C=O), 1625 (m), 1475 (m), 1270 (m), 1120 (m) cm−1; HRMS (FAB+)
m/z [M]+ calcd for C32H29N5O7S2 659.1058, found 659.1071.
Acknowledgements
For financial support, we thank Ministry of Science and Technology (MOST, Grant
Nos. 106-2113-M-007-011-MY2 and 107-3017-F-007-002), Ministry of Education (Grant
Nos. 106N501CE1 and 107QR001I5) of R.O.C., and the European Commission SILVER
project within the 7th Framework Programme as Cooperation Project Grant Agreement (grant
No. 103G603-14). We also thank the Ministry of Education and MOST in Taiwan to
support The Featured Areas Research Center Program within the framework of the Higher
Education Sprout Project through the Frontier Research Center on Fundamental and Applied
Sciences of Matters.
Appendix A. Supporting Information
Supplementary data associated with this article can be found in the online version.
References
[1] O. Schwartz, M.L. Albert, Biology and pathogenesis of chikungunya virus, Nat. Rev.
Microbiol. 8 (2010) 491–500.
[2] J.A. Cardona-Ospina, W.E. Villamil-Gómez, C.E. Jimenez-Canizales, D.M. Castañeda–
Hernández, A.J. Rodríguez-Morales, Estimating the burden of disease and the economic
cost attributable to chikungunya, Colombia, Trans. R. Soc. Trop. Med. Hyg. 109 (2015)
793–802.
[3] J.H. Erasmus, A.J. Auguste, J.T. Kaelber, H. Luo, S.L. Rossi, K. Fenton, G. Leal, D.Y.
Kim, W. Chiu, T. Wang, I. Frolov, F. Nasar, S.C. Weaver, A chikungunya fever vaccine
utilizing an insect-specific virus platform, Nat. Med. 23 (2017) 192–199.
[4] J.R. Hwu, T.K. Pradhan, S.-C., Tsay, M. Kapoor, S.O. Bachurin, O.A. Raevsky, J.
Neyts, Antiviral agents towards chikungunya virus: structures, syntheses, and
isolation from natural sources, in: K. Tomioka, T. Shioiri, H. Sajiki (Eds.), New
Horizons of Process Chemistry: Scalable Reactions and Technologies, Springer
Nature, Singapore, 2017, pp. 251–274.
[5] S. Ozden, M. Lucas-Hourani, P.-E. Ceccaldi, A. Basak, M. Valentine, S. Benjannet, J.
13

ACCEPTED MANUSCRIPT
Hamelin, Y. Jacob, K. Mamchaoui, V. Mouly, P. Desprès, A. Gessain, G.
Butler-Browne, M. Chrétien, F. Tangy, P.-O. Vidalain, N.G. Seidah, Inhibition of
Chikungunya virus infection in cultured human muscle cells by furin inhibitors:
impairment of the maturation of the E2 surface glycoprotein, J. Biol. Chem. 283 (2008)
21899–21908.
[6] a) M. Bourjot, P. Leyssen, C. Eydoux, J. C. Guillemot, B. Canard, P. Rasoanaivo, F.
Guéritte, M. Litaudon, Chemical constituents of Anacolosa pervilleana and their
antiviral activities, Fitoterapia 83 (2012) 1076–1080; b) K.S. Murali, S.
Sivasubramanian, S. Vincent, S.B. Murugan, B. Giridaran, S. Dinesh, P. Gunasekaran,
K. Krishnasamy, R. Sathishkumar, Anti-chikungunya activity of luteolin and apigenin
rich fraction from Cynodon dactylon, Asian Pac. J. Trop. Med. 8 (2015) 352–358; c) L.
Pohjala, A. Utt, M. Varjak, A. Lulla, A. Merits, T. Ahola, P. Tammela, Inhibitors of
alphavirus entry and replication identified with a stable Chikungunya replicon cell line
and virus-based assays, PLoS One 6 (2011) e28923; d) M. Madariaga, E. Ticona, C.
Resurrecion, Chikungunya: bending over the Americas and the rest of the world, Braz.
J. Infect. Dis. 20 (2016) 91–99; e) M. Bourjot, P. Leyssen, J. Neyts, V. Dumontet, M.
Litaudon, Trigocherrierin A, a potent inhibitor of chikungunya virus replication,
Molecules 19 (2014) 3617–3627.
[7] E.F. da Silva-Júnior, G.O. Leoncini, É.E.S. Rodrigues, T.M. Aquino, J.X. Araújo-Júnior,
The medicinal chemistry of chikungunya virus, Bioorg. Med. Chem. 25 (2017) 4219–
4244.
[8] a) A. Gigante, A. Gómez-SanJuan, L. Delang, C. Li, O. Bueno, A.M. Gamo, E.-M.
Priego, M.-J. Camarasa, D. Jochmans, P. Leyssen, E. Decroly, B. Coutard, G. Querat, J.
Neyts, M.-J. Pérez-Pérez, Antiviral activity of [1,2,3]triazolo[4,5-d]pyrimidin-
7(6H)-ones against chikungunya virus targeting the viral capping nsP1, Antivir. Res.
144 (2017) 216–222; b) K.-C. Ching, T.N.Q. Tran, S.N. Amrun, Y.-W. Kam, L.F.P. Ng,
C.L.L. Chai, Structural optimizations of thieno[3,2-b]pyrrole derivatives for the
development of metabolically stable inhibitors of chikungunya virus, J. Med. Chem. 60
(2017) 3165–3186; c) J.R. Hwu, N.K. Gupta, S.-C. Tsay, W.-C. Huang, I.C. Albulescu,
K. Kovacikova, M.J. van Hemert, Bis(benzofuran-thiazolidinone)s and bis(benzofuran–
thiazinanone)s as inhibiting agents for chikungunya virus, Antivir. Res. 146 (2017) 96–
101.
[9] M.-S. Louvet, G. Gault, S. Lefebvre, F. Popowycz, M. Boulven, S. Besse, E. Benoit, V.
Lattard, D. Grancher, Comparative inhibitory effect of prenylated coumarins, ferulenol
and ferprenin, contained in the ‘poisonous chemotype’ of Ferula communis on mammal
liver microsomal VKORC1 activity, Phytochemistry 118 (2015) 124–130.
[10] a) S.S. Bhattacharyya, S. Paul, S.K. Mandal, A. Banerjee, N. Boujedaini, A.R.
Khuda-Bukhsh, A synthetic coumarin (4-methyl-7 hydroxy coumarin) has anti-cancer
potentials against DMBA-induced skin cancer in mice, Eur. J. Pharmacol. 614 (2009)
14

ACCEPTED MANUSCRIPT
128–136; b) H. Morohashi, A. Kon, M. Nakai, M., Yamaguchi, I. Kakizaki, S.
Yoshihara, M. Sasaki, K. Takagaki, Study of hyaluronan synthase inhibitor,
4-methylumbelliferone derivatives on human pancreatic cancer cell (KP1-NL),
Biochem. Biophys. Res. Commun. 45 (2006) 1454–1459.
[11] M.Z. Hassan, H. Osman, M.A. Ali, M.J. Ahsan, Therapeutic potential of coumarins as
antiviral agents, Eur. J. Med. Chem. 123 (2016) 236–255.
[12] For anti-CHIKV, see: J.R. Hwu, M. Kapoor, S.-C. Tsay, C.-C. Lin, K.C. Hwang, J.-C.
Horng, I.-C. Chen, F.-K. Shieh, P. Leyssen, J. Neyts, Benzouracil−coumarin−arene
conjugates as inhibiting agents for chikungunya virus, Antivir. Res. 118 (2015) 103–
109.
[13] For anti-HCV, see: a) J.R. Hwu, R. Singha, S.C. Hong, Y.H. Chang, A.R. Das, I.
Vliegen, E. De Clercq, J. Neyts, Synthesis of new benzimidazole–coumarin conjugates
as anti-hepatitis C virus agents, Antivir. Res. 77 (2008) 157–162; b) J. Neyts, E. De
Clercq, R. Singha, Y.H. Chang, A.R. Das, S.K. Chakraborty, S.C. Hong, S.-C. Tsay,
M.-H. Hsu, J.R. Hwu, Structure-activity relationship of new anti-hepatitis C virus
agents: heterobicycle-coumarin conjugates, J. Med. Chem. 52 (2009) 1486–1490; c) J.R.
Hwu, S.-Y. Lin, S.-C. Tsay, E. De Clercq, P. Leyssen, J. Neyts, Coumarin–purine
ribofuranoside conjugates as new agents against hepatitis C virus, J. Med. Chem. 54
(2011) 2114–2126; d) J.R. Hwu, S.-Y. Lin, S.-C., Tsay, R. Singha, B.K. Pal, P. Leyssen,
J. Neyts, Development of new sulfur-containing conjugated compounds as anti-HCV
agents, Phosphorus Sulfur Silicon Relat. Elem. 186 (2011) 1144–1152; e) S.-C. Tsay,
J.R. Hwu, R. Singha, W.-C. Huang, Y.H. Chang, M.-H. Hsu, F.-K. Shieh, C.-C. Lin,
K.C. Hwang, J.-C. Horng, E. De Clercq, I. Vliegen, J. Neyts, Coumarins hinged directly
on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus, Eur. J. Med.
Chem. 63 (2013) 290–298; f) S.-C. Tsay, S.-Y. Lin, W.-C. Huang, M.-H. Hsu, K.C.
Hwang, C.-C. Lin, J.-C. Horng, I.-C. Chen, J.R. Hwu, F.-K. Shieh, P. Leyssen, J. Neyts,
Synthesis and structure−activity relationship of imidazole–coumarin conjugates against
hepatitis C virus, Molecules 21 (2016) 228; g) S.-C. Tsay, W.-C. Huang, J. Neyts, J.R.
Hwu, New conjugated compounds coming on stream against hepatitis C virus, SM J.
Hepat. Res. Treat. 2 (2016) 1009.
[14] For anti-HIV see: a) T.J. Rashamuse, R. Klein, P.T. Kaye, Synthesis of baylis–
hillman-derived phosphonated 3-(benzylaminomethyl)coumarins, Synth. Commun. 40
(2010) 3683–3690; b) S. Thaisrivongs, P.K. Tomich, K.D. Watenpaugh, K.T. Chong,
W.J. Howe, C.P. Yang, J.W. Strohbach, S.R. Turner, J.P. McGrath, M.J. Bohanon, J.C.
Lynn, A.M. Mulichak, P.A. Spinelli, R.R. Hinshaw, P.J. Pagano, J.B. Moon, M.J.J.
Ruwart, K.F. Wilkinson, B.D. Rush, G.L. Zipp, R.J. Dalga, F.J. Schwende, G.M.
Howard, G.E. Padbury, L.N. Toth, Z. Zhao, K.A. Koeplinger, T.J. Kakuk, S.L. Cole,
R.M. Zaya, R.C. Piper, P. Jeffrey, Structure-based design of HIV protease inhibitors:
4-hydroxycoumarins and 4-hydroxy-2-pyrones as nonpeptidic inhibitors, J. Med. Chem.
15

ACCEPTED MANUSCRIPT
37 (1994) 3200–3204.
[15] O.M. Abdelhafez, K.M. Amin, R.Z. Batran, T.J. Maher, S.A. Nada, S. Sethumadhavan,
Synthesis, anticoagulant and PIVKA-II induced by new 4-hydroxycoumarin
derivatives, Bioorg. Med. Chem. 18 (2010) 3371–3378.
[16] A. Arshad, H. Osman, M.C. Bagley, C.K. Lam, S. Mohamad, A.S.M. Zahariluddin,
Synthesis and antimicrobial properties of some new thiazolyl coumarin derivatives, Eur.
J. Med. Chem. 46 (2011) 3788–3794.
[17] T. Matsumoto, K. Takahashi, S. Kanayama, Y. Nakano, H. Imai, M. Kibi, D. Imahori, T.
Hasei, T. Watanabe, Structures of antimutagenic constituents in the peels of Citrus
limon, J. Nat. Med. 71 (2017) 735–744.
[18] Y. Chen, H.-R. Liu, H.-S. Liu, M. Cheng, P. Xia, K. Qian, P.-C. Wu, C.-Y. Lai, Y. Xia,
Z.-Y. Yang, S.L. Morris-Natschke, K.-H. Lee, Antitumor agents 292. Design, synthesis
and pharmacological study of S- and O-substituted 7-mercapto- or hydroxy-coumarins
and chromones as potent cytotoxic agents, Eur. J. Med. Chem. 49 (2012) 74–85.
[19] R.S. Keri, B.S. Sasidhar, B.M. Nagaraja, M.A. Santos, Recent progress in the drug
development of coumarin derivatives as potent antituberculosis agents, Eur. J. Med.
Chem. 100 (2015) 257–269.
[20] P.O. Patil, S.B. Bari, S.D. Firke, P.K. Deshmukh, S.T. Donda, D.A. Patil, A
comprehensive review on synthesis and designing aspects of coumarin derivatives as
monoamine oxidase inhibitors for depression and Alzheimer’s disease, Bioorg. Med.
Chem. 21 (2013) 2434–2450.
[21] A. Sunthitikawinsakul, N. Kongkathip, B. Kongkathip, S. Phonnakhu, J.W. Daly, T.F.
Spande, Y. Nimit, S. Rochanaruangrai, Coumarins and carbazoles from Clausena
excavata exhibited antimycobacterial and antifungal activities, Planta Med. 69 (2003)
155–157.
[22] Y.K. Al-Majedy, A.A. Al-Amiery, A.A.H. Kadhum, A.B. Mohamad, Antioxidant
activities of 4-methylumbelliferone derivatives, PLoS ONE 11 (2016) e0156625.
[23] I. Najmanova, M. Dosedel, R. Hrdina, P. Anzenbacher, T. Filipsky, M. Ríha, P.
Mladenka, Cardiovascular effects of coumarins besides their antioxidant activity, Curr.
Top. Med. Chem. 15 (2015) 830–849.
[24] L. Xie, X. Qian, J. Cui, Y. Xiao, K. Wang, P. Wu, L. Cong, Novel angular
furoquinolinones bearing flexible chain as antitumor agent: design, synthesis, cytotoxic
evaluation, and DNA-binding studies, Bioorg. Med. Chem. 16 (2008) 8713–8718.
[25] a) D.L. Lancaster, N. Patel, L. Lennard, J.S. Lilleyman, 6-Thioguanine in children with
acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and
6-thioguanine nucleotide concentrations, Br. J. Clin. Pharmacol. 51 (2001) 531–539; b)
N.K.H. de Boer, C.M.J. van Nieuwkerk, M.N. Aparicio Pages, S.Y. de Boer, L.J.J.
Derijks, C.J.J. Mulder, Promising treatment of autoimmune hepatitis with 6-thioguanine
after adverse events on azathioprine, Eur. J. Gastroenterol. Hepatol. 17 (2005) 457–461;
16

ACCEPTED MANUSCRIPT
c) Q.-e. Yang, K.-g. Li, J.A. Mikovits, Eradication of human immunodeficiency virus
type 1-infected cells by a combination of antimetabolic cytotoxic chemotherapy and
antiviral chemotherapy in vitro: a pilot study, J. Infect. Dis. 186 (2002) 706–709.
[26] L. Chang, S.-Y. Lee, P. Leonczak, J. Rozenski, S. De Jonghe, T. Hanck, C.E. Müller, P.
Herdewijn, Imidazopyridine- and purine-thioacetamide derivatives: potent inhibitors of
nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1), J. Med. Chem. 57 (2014)
10080–10100.
[27] D.E. Bergstrom, A.J. Brattesani, Halogenation of tubercidin by N-halosuccinimides. A
direct route to 5-bromotubercidin, a reversible inhibitor of RNA synthesis in eukaryotic
cells, Nucleic Acids Res. 8 (1980) 6213–6219.
[28] R.E. Holmes, R.K. Robins, Purine nucleosides. VII. direct bromination of adenosine,
deoxyadenosine, guanosine, and related purine nucleosides, J. Am. Chem. Soc. 86
(1964) 1242–1245.
[29] T. Giorgi, S. Lena, P. Mariani, M.A. Cremonini, S. Masiero, S. Pieraccini, J.P. Rabe, P.
Samorì, G.P., Spada, G. Gottarelli, Supramolecular helices via self-assembly of
8-oxoguanosines, J. Am. Chem. Soc. 125 (2003) 14741–14749.
[30] a) A.B. Reitz, M.G. Goodman, B.L. Pope, D.C. Argentieri, S.C. Bell, L.E. Burr, E.
Chourmouzis, J. Come, J.H. Goodman, D.H. Klaubert, B.E. Maryanoff, M.E.
McDonnell, S.M.S. Rampulla, M.R. Schott, R. Chen, Small-molecule
immunostimulants. Synthesis and activity of 7,8-disubstituted guanosines and
structurally related compounds, J. Med. Chem. 37 (1994) 3561–3578; b) H.-G.
Genieser, E. Butt, U. Bottin, W. Dostmann, B. Jastorff, Synthesis of the 3',5'-cyclic
phosphates from unprotected nucleosides, Synthesis (1989) 53–54.
[31] H. Vorbrüggen, K. Krolikiewicz, B. Bennua, Nucleoside Syntheses, XXII Nucleoside
synthesis with trimethylsilyl triflate and perchlorate as catalysts, Chem. Ber. 114 (1981)
1234–1255.
[32] R.M. Silverstein, F.X. Webster, D.J. Kiemle, Spectrometric Identification of Organic
Compounds, 7th ed., John Wiley, New York, 2005, p. 98.
[33] M. Bassetto, T. De Burghgraeve, L. Delang, A. Massarotti, A. Coluccia, N. Zonta, V.
Gatti, G. Colombano, G. Sorba, R. Silvestri, G.C. Tron, J. Neyts, P. Leyssen, A.
Brancale, Computer-aided identification, design and synthesis of a novel series of
compounds with selective antiviral activity against chikungunya virus, Antivir. Res. 98
2013) 12–18.
[34] M.M. Hann, G.M. KeserüesFinding the sweet spot: the role of nature and nurture in
medicinal chemistry, Nat. Rev. Drug Discov. 11 (2012) 355–365.
[35] A.K. Ghose, V.N. Viswanadhan, J.J. Wendoloski, A knowledge-based approach in
designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A
qualitative and quantitative characterization of known drug databases, J. Comb. Chem.
17

ACCEPTED MANUSCRIPT
1 (1999) 55–68.
[36] P. Leeson, Drug discovery: chemical beauty contest, Nature 481 (2012) 455–456.
[37] M. Kraszni, I. Bányai, B. Noszál, Determination of conformer-specific partition
coefficients in octanol/water systems, J. Med. Chem. 46 (2003) 2241–2245.
[38] C.A. Lipinski, Drug-like properties and the causes of poor solubility and poor
permeability, J. Pharmacol. Toxicol. Methods. 44 (2000) 235–249.
18

ACCEPTED MANUSCRIPT
Highlights
• New coumarin−guanosine conjugates were designed and synthesized.
• Three new conjugates showed potent inhibitory activity towards
chikungunya virus.
• Coumarin is an essential moiety for new conjugated compounds with
activity against chikungunya virus.
• Attachment of a methoxy group to the coumarin moiety enhanced the
activity against chikungunya virus.